BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · BBIO · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
162
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
BridgeBio Pharma, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
BBIO insider buying and selling by quarter
BBIO insider selling · BBIO insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · BBIO ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
BBIO executive sell shares · BBIO board member insider trading · BBIO insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 2,256 | $152K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 6,725 | $459K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 5,072 | $351K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 11,250 | $793K | Form 4 |
| May 21, 2026 | Kumar Neil CEO · Director | Sale | 800 | $57K | Form 4 |
| May 16, 2026 | Trimarchi Thomas President and CFO | Other | 22,781 | $1.51M⚡ | Form 4 |
| May 18, 2026 | Trimarchi Thomas President and CFO | Sale | 10,456 | $678K | Form 4 |
| May 18, 2026 | Trimarchi Thomas President and CFO | Sale | 3,195 | $211K | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 6,519 | — | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 11,553 | — | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 19,599 | — | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Other | 36,236 | $2.40M⚡ | Form 4 |
| May 16, 2026 | Kumar Neil CEO · Director | Option | 33,544 | — | Form 4 |
| May 16, 2026 | Apuli Maricel CAO | Other | 4,714 | $312K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Option | 10,000 | $168K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 6,200 | $413K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 2,088 | $141K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 1,512 | $103K | Form 4 |
| May 15, 2026 | Scott Randal W. Director | Sale | 200 | $14K | Form 4 |
| May 7, 2026 | Kumar Neil CEO · Director | Sale | 11,217 | $757K | Form 4 |
| May 7, 2026 | Kumar Neil CEO · Director | Sale | 8,334 | $570K | Form 4 |
| May 7, 2026 | Kumar Neil CEO · Director | Sale | 449 | $31K | Form 4 |
| May 8, 2026 | Kumar Neil CEO · Director | Sale | 13,974 | $931K | Form 4 |
| May 8, 2026 | Kumar Neil CEO · Director | Sale | 5,076 | $342K | Form 4 |
| May 8, 2026 | Kumar Neil CEO · Director | Sale | 950 | $65K | Form 4 |
Trimarchi Thomas
President and CFO
Date
May 16
Shares
22,781
Price
$66.13
Value
$1.51M ⚡
Trimarchi Thomas
President and CFO
Date
May 18
Shares
10,456
Price
$64.82
Value
$678K
Trimarchi Thomas
President and CFO
Date
May 18
Shares
3,195
Price
$65.95
Value
$211K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About BBIO insider trading
BBIO insider trades
BridgeBio Pharma, Inc. (BBIO) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Kumar Neil (CEO · Director), Scott Randal W. (Director), Trimarchi Thomas (President and CFO). Over the past 12 months, 5 insiders have filed transactions with the SEC. BBIO insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For BridgeBio Pharma, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
BBIO insider trading · 5 questionsThe insiders of BridgeBio Pharma, Inc. (BBIO) include executives and directors such as Kumar Neil (CEO · Director), Scott Randal W. (Director), Trimarchi Thomas (President and CFO), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026